checkAd

Satellos Biosciences (früher: Ico Therapeutics) - innovative Therapien für neue Herausforderungen in

eröffnet am 09.02.15 23:02:22 von
neuester Beitrag 07.09.21 17:42:35 von

Beitrag zu dieser Diskussion schreiben


  • 1
  • 27

Begriffe und/oder Benutzer

 

Fragen

 Ja Nein
Avatar
07.09.21 17:42:35
Beitrag Nr. 264 ()
Avatar
02.09.21 11:07:54
Beitrag Nr. 263 ()
Antwort auf Beitrag Nr.: 69.174.965 von Made75 am 28.08.21 10:30:37Der Kurs der Aktie muss sich finden - so wie es scheint haben oder schmeissen einige Altaktionäre die Aktie noch.

Erste Stabilisierungsversuche sind zwar zu sehen, stehen aber noch auf töneren Füssen. Kann natürlich auch wieder Anspringen - mit den entsprechenden News.
Avatar
28.08.21 10:30:37
Beitrag Nr. 262 ()
Antwort auf Beitrag Nr.: 69.167.261 von Made75 am 27.08.21 13:26:54https://start.mytomorrows.com/patienten-behandlungen-in-entw…


Zur Info ein Link der die Krankheit erklärt
1 Antwort
Avatar
27.08.21 13:26:54
Beitrag Nr. 261 ()
https://www.newsfilecorp.com/release/94605/Satellos-Bioscien…

Na dann Schritt für Schritt vorwärts 👍
2 Antworten
Avatar
23.08.21 19:19:03
Beitrag Nr. 260 ()
aus 20000 wurden
1000 kurs 1,63 scheiß aktie
Avatar
22.08.21 16:24:29
Beitrag Nr. 259 ()
Antwort auf Beitrag Nr.: 69.104.474 von inkognito007 am 20.08.21 09:08:46Nix dazu gefunden.

Wer einen Link hat bitte gerne einsitellen.

Der Kurs rauscht trotz der News erst mal runter. Mal sehen, wie es weiter geht.
Avatar
21.08.21 07:47:43
Beitrag Nr. 258 ()
Antwort auf Beitrag Nr.: 69.095.501 von Indextrader24 am 19.08.21 12:35:51Sparkasse...

Umstellung am Fr.

Schönes WE, mdn
Avatar
20.08.21 09:08:46
Beitrag Nr. 257 ()
https://www.wsj.com/market-data/quotes/CA/XTSX/MSCL/research…

jemand die Möglichkeit die Analyse zu recherchieren mit DIESEM:eek: Kursziel ?
1 Antwort
Avatar
19.08.21 15:35:33
Beitrag Nr. 256 ()
Antwort auf Beitrag Nr.: 69.097.007 von inkognito007 am 19.08.21 14:31:39
Satellos Biosciences steigt ins Cannabisgeschäft ein...
Das geht aber jetzt hier Schlag auf Schlag

nicht nur Immunmodulation und Antiinfektiva im Bereich Leishmaniose und Co bis hin zur möglichen SARS-CoV-2 Behandlung mittels AmphoB und seinen möglichen antiviralen Effekten.

Jetzt zusäzlich zur Entwicklung neuer Therapien gegen Muskelschwund auch noch der Einstieg in den milliardenschweren CBD Markt.

Das Unternehmen scheint sich breiter aufstellen zu wollen, als ob man ein global agierendes Pharmaunternehmen eines Tages werden will.

Interessante Entwicklung.

Zitat aus der Pressemitteilung:

Satellos to develop oral CBD with NW PharmaTech

2021-08-18 16:21 ET - News Release


Mr. Frank Gleeson reports

SATELLOS BIOSCIENCE ANNOUNCES JOINT DEVELOPMENT AGREEMENT WITH NW PHARMATECH LIMITED FOR ORAL CBD

Satellos Bioscience Inc., formerly iCo Therapeutics Inc., and NW PharmaTech Ltd. have noted that Amphotericin B Technologies Inc. (AmpB Tech), a wholly owned subsidiary of Satellos established to accelerate the development of its novel and proprietary oral transport technology (OralTrans), has entered into a joint development agreement with NW PharmaTech to develop an oral formulation of cannabidiol (CBD) for the over-the-counter market. Oral CBD will initially target the global market for sleep aids, estimated at $3-billion in 2020. NW PharmaTech has agreed to provide an up-front payment and finance development costs of the formulation and testing for safety, toxicity, and pharmacokinetics.

"Our partnership with NW PharmaTech is an important extension of our strategy to provide solutions for the oral delivery of non-water soluble compounds in areas of high demand, and allows us to enter an exciting and expanding new market of great potential with a key partner," said William Jarosz, the president and chief executive officer of AmpB Tech.

"We are excited about our partnership with AmpB Tech which will enable us to work towards improving the bioavailability of CBD which is critical in unlocking the true potential of the molecule," noted Filipp Korentsvit, one of the founding partners of NW PharmaTech.

In addition, AmpB Tech is pleased to announce that its scientific abstract entitled, "Amphotericin B Inhibits SARS-CoV 2 Replication within Kidney Vero Cells," has been accepted for poster presentation at the prestigious 2021 AAPS PharmSci 360, from Oct. 17 to Oct. 20, 2021.

"Together, these developments provide tangible evidence for the interest in OralTrans and illustrate why Satellos established AmpB Tech as the commercialization vehicle to create value for this exciting platform and benefit shareholders," commented Frank Gleeson, the president and chief executive officer of Satellos.

"We are looking forward to applying our novel drug delivery technology to these and additional new indications," noted Dr. Kishor M. Wasan, co-inventor of the drug delivery technology, distinguished university scholar, adjunct professor at the University of British Columbia and chief science officer of AmpB Tech.

AmpB Tech and NW PharmaTech will begin their joint development of oral CBD immediately.

About Amphotericin B Technologies Inc.

AmpB Tech is a wholly owned subsidiary of Satellos. It was established to be the sole commercial development vehicle for a patent-protected, proprietary oral transport technology, OralTrans, invented by its chief scientific officer Dr. Kishor Wasan. AmpB Tech has applied its technology to the oral formulation of Amphotericin B, a systemically delivered anti-fungal agent used to treat serious fungal infections. In phase Ia and Ib clinical trials in humans, AmpB Tech's oral formulation of Amphotericin B was shown to be safe at therapeutic doses with a potentially reduced toxicity profile. AmpB Tech is actively seeking development and financing partners to expand OralTrans to other areas of significant medical or market need.

About Satellos Bioscience Inc.

Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity -- a process that balances replenishment of muscle stem cells and production of specialized tissue cells -- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem-cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc. Founded in 2018, Satellos is headquartered in Canada.
Avatar
19.08.21 14:31:39
Beitrag Nr. 255 ()
Entschuldigung.....der sollte es sein....


https://cdn-ceo-ca.s3.amazonaws.com/1ghsfos-4A01ED22-1790-4C…
1 Antwort
  • 1
  • 27
 DurchsuchenBeitrag schreiben


Satellos Biosciences (früher: Ico Therapeutics) - innovative Therapien für neue Herausforderungen in